Skip to main content
. 2022 Mar 30;92(2):164–172. doi: 10.1002/ana.26352

FIGURE 1.

FIGURE 1

Use of preferred disease‐modifying treatments (DMTs). This graph depicts the annual proportion of patients treated with preferred DMTs as defined by the 2013 expert‐led preferred formulary (lowest priced interferon‐beta and/or glatiramer acetate product, natalizumab and rituximab) in the MS Treatment Optimization Program (MSTOP) intervention region (Kaiser Permanente Southern California [KPSC], blue line) and the Kaiser Permanente (KP) comparator (green line). Adherence to the preferred formulary within KPSC improved following MSTOP endorsement and spread in 2013. In the comparator, adherence to the preferred formulary improved from 2016 to 2018 with the assignment of clinical pharmacy support and endorsement of MSTOP in 2018. The timeline begins in 2010 because this is when the first DMT was designated as the preferred KP agent (by health plan pharmacy based on price).